List of Genosyl drug patents

Genosyl is owned by Vero Biotech.

Genosyl contains Nitric Oxide.

Genosyl has a total of 22 drug patents out of which 1 drug patent has expired.

Expired drug patents of Genosyl are:

  • US6758214

Genosyl was authorised for market use on 20 December, 2019.

Genosyl is available in gas;inhalation dosage forms.

Genosyl can be used as a method of delivering nitric oxide to a patient, a method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia.

The generics of Genosyl are possible to be released after 12 February, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6758214 VERO BIOTECH Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
Feb, 2022

(1 year, 25 days ago)

US11383059 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US8609028 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US9522249 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US8821801 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US9956373 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US11291793 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US8226916 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US10124142 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(2 years from now)

US10814092 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2025

(2 years from now)

US8057742 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2026

(2 years from now)

US7947227 VERO BIOTECH Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(3 years from now)

US7618594 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(3 years from now)

US7560076 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Apr, 2027

(4 years from now)

US9701538 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2029

(5 years from now)

US9604028 VERO BIOTECH Systems and devices for generating nitric oxide
Aug, 2029

(6 years from now)

US10926054 VERO BIOTECH Systems and devices for generating nitric oxide
Aug, 2029

(6 years from now)

US8944049 VERO BIOTECH Systems and devices for generating nitric oxide
Aug, 2029

(6 years from now)

US11103669 VERO BIOTECH Nitric oxide therapies
Jun, 2030

(7 years from now)

US8607785 VERO BIOTECH Systems and devices for generating nitric oxide
Jul, 2030

(7 years from now)

US10737051 VERO BIOTECH Nitrogen dioxide storage device
Oct, 2035

(12 years from now)

US10213572 VERO BIOTECH Nitrogen dioxide storage cassette
Feb, 2036

(12 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient; A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

55

United States

12

Japan

8

Australia

7

European Union

6

Canada

Genosyl is owned by Vero Biotech Inc.

Genosyl contains Nitric Oxide.

Genosyl has a total of 1 drug patent out of which 0 drug patents have expired.

Genosyl was authorised for market use on 20 December, 2019.

Genosyl is available in gas;inhalation dosage forms.

The generics of Genosyl are possible to be released after 21 September, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11511252 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Sep, 2029

(6 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in